177Lu-PSMA-617 Provides Comparable OS Benefit to Cabazitaxel in mCRPC Progressing After Docetaxel
June 5th 2022
177Lu-PSMA-617 represents an acceptable option for patients with metastatic castration-resistant prostate cancer who are progressing after docetaxel, as it has been shown to provide similar overall survival benefit to that of cabazitaxel, with a stronger progression-free survival benefit and fewer toxicities